Company: CDLX
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001666071-25-000126
Chunk: 101

Company: Cardlytics, Inc.
Filing Date: 2025-08-06
Form: 10-Q
Item: Item 1
Chunk 101
---
umulated deficit(1,323,141)(1,300,576)Total stockholders’ equity58,706 69,993 Total liabilities and stockholders’ equity$361,134 $392,711 

See notes to the condensed consolidated financial statements3

Table of Contents

CARDLYTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

(Amounts in thousands, except per share amounts)

 Three Months EndedJune 30,Six Months EndedJune 30, 2025202420252024Revenue$63,249 $69,636 $125,147 $137,244 Costs and expenses:Partner Share and other third-party costs27,103 33,258 56,553 63,801 Delivery costs6,883 7,661 14,171 13,834 Sales and marketing expense11,335 14,025 24,089 28,143 Research and development expense11,295 13,470 23,001 26,518 General and administrative expense12,905 16,151 26,683 30,636 Acquisition, integration and divestiture costs— 162 — 162 Change in contingent consideration42 (5,808)102 9 Loss (gain) on disposal or divestiture200 — (5,150)— Depreciation and amortization expense6,275 6,529 12,566 12,779 Total costs and expenses76,038 85,448 152,015 175,882 Operating Loss(12,789)(15,812)(26,868)(38,638)Other income (expense):Interest expense, net(1,943)(1,561)(3,773)(2,380)Foreign currency gain (loss)5,449 99 8,076 (531)Gain on debt extinguishment— 13,017 — 13,017 Total other income3,506 11,555 4,303 10,106 Loss before income taxes(9,283)(4,257)(22,565)(28,532)Net Loss$(9,283)$(4,257)$(22,565)$(28,532)Net Loss per share, basic and diluted$(0.18)$(0.09)$(0.43)$(0.62)Weighted